Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

O-mannosylation and protein maturation check-points represent therapeutic opportunities in BRAF fusion protein oncogenesis

by Parikh, Julie , Bahadur, Sher , Ligon, Keith , Elsadek, Lobna , Miglietta, Esteban , Jones, Jacquelyn , Gonzales, Elizabeth M. , Lee, Joohee , Kalani, Zohra , Ragnoni, Timothy J. , Ozdemir, Merve , Novikov, Dana , Dengjel, Jörn , Janeway, Katherine , Cimini, Beth A. , Misek, Sean A. , Choi, Seung Hyun , Milde, Till , Kyrila, Gloria , Fischer, Eric , Joshi, Hiren J. , Beroukhim, Rameen , Bandopadhayay, Pratiti , Golub, Todd , Hahn, William C. , Brummer, Tilman , Halim, Adnan , Eck, Michael , Zhang, Alexander , Clausen, Henrik , Jones, David T.W. , Vakhrushev, Sergey , Vallurupalli, Mounica , Robinson, Jenna , Cai, Kelly , Tang, Kira , Christen, Daniel , Fultineer, Aaron , Borgenvik, Anna , Persky, Nicole , Jeon, Hyesung , Abid, Tanaz , Reel, Sarah , Apfelbaum, April , Maldera, Antonio , Kwon, Jason , Zhou, Kevin , Stumpe, Michael , Condurat, Alexandra Larisa , Boehm, Jesse S. , Carpenter, Anne , Phoenix, Timothy N. , Goodale, Amy , Jabado, Nada , Eisenbies, Zachary , Bondeson, Daniel , Pal, Sangita , Root, David , de la Vega, Lorena Lazo , Malinowski, Seth , Boisvert, Michelle

in Cancer Biology

2025

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

O-mannosylation and protein maturation check-points represent therapeutic opportunities in BRAF fusion protein oncogenesis

in Cancer Biology

2025

Confirm

Do you wish to request the book?

O-mannosylation and protein maturation check-points represent therapeutic opportunities in BRAF fusion protein oncogenesis

in Cancer Biology

2025

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Paper

O-mannosylation and protein maturation check-points represent therapeutic opportunities in BRAF fusion protein oncogenesis

Parikh, Julie,

Bahadur, Sher,

Ligon, Keith,

Elsadek, Lobna,

Miglietta, Esteban,

Jones, Jacquelyn,

Gonzales, Elizabeth M.,

Lee, Joohee,

Kalani, Zohra,

Ragnoni, Timothy J.,

Ozdemir, Merve,

Novikov, Dana,

Dengjel, Jörn,

Janeway, Katherine,

Cimini, Beth A.,

Misek, Sean A.,

Choi, Seung Hyun,

Milde, Till,

Kyrila, Gloria,

Fischer, Eric,

Joshi, Hiren J.,

Beroukhim, Rameen,

Bandopadhayay, Pratiti,

Golub, Todd,

Hahn, William C.,

Brummer, Tilman,

Halim, Adnan,

Eck, Michael,

Zhang, Alexander,

Clausen, Henrik,

Jones, David T.W.,

Vakhrushev, Sergey,

Vallurupalli, Mounica,

Robinson, Jenna,

Cai, Kelly,

Tang, Kira,

Christen, Daniel,

Fultineer, Aaron,

Borgenvik, Anna,

Persky, Nicole,

Jeon, Hyesung,

Abid, Tanaz,

Reel, Sarah,

Apfelbaum, April,

Maldera, Antonio,

Kwon, Jason,

Zhou, Kevin,

Stumpe, Michael,

Condurat, Alexandra Larisa,

Boehm, Jesse S.,

Carpenter, Anne,

Phoenix, Timothy N.,

Goodale, Amy,

Jabado, Nada,

Eisenbies, Zachary,

Bondeson, Daniel,

Pal, Sangita,

Root, David,

de la Vega, Lorena Lazo,

Malinowski, Seth,

Boisvert, Michelle

2025

Overview

Fusions between protein-coding genes are common oncogenic drivers across cancers, typically pairing a proto-oncogene with partner that does not independently drive cancer. In all therapeutically actionable fusions, the proto-oncogene is the drug target, the contributions to oncogenicity of the fusion partner have largely been ignored. We studied the role of BRAF fusion partners and found that they are necessary for transformation. In the setting of KIAA1549::BRAF, the most common fusion protein across brain tumors, we found that KIAA1549 is necessary for the oncogenicity of KIAA1549::BRAF and engenders a striking and specific dependency on the protein O-mannosyltransferase complex (POMT1/2). Specifically, we show that genetic silencing or pharmacologic inhibition of the protein O-mannosyltransferase complex (POMT1/2) reverses fusion-induced transformation, thereby representing a novel and MAPK independent therapeutic target. Furthermore, POMT1/2 is required to glycosylate and enable maturation of the K::B fusion protein. These findings represent a proof-of-concept for targeting the partners in oncogenic fusions as a potential cancer therapeutic strategy.

Share this book

Add to My Shelf

Publisher

Cold Spring Harbor Laboratory

Subject

Cancer Biology